Two-tablet INSTI-based therapy in adults
If the single-tablet INSTI-based regimens are not suitable, the following regimens are also effective as initial therapy. In adults, use1:
emtricitabine+tenofovir alafenamide (Descovy) 200 mg+25 mg orally, daily. For dosage adjustment in adults with kidney impairment, see emtricitabine+tenofovir alafenamide dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy emtricitabine + tenofovir alafenamide (Descovy) emtricitabine+tenofovir alafenamide (Descovy) emtricitabine+tenofovir alafenamide (Descovy)
PLUS EITHER
1dolutegravir (Tivicay) 50 mg orally, daily. For dosage adjustment in adults with kidney impairment, see dolutegravir dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy dolutegravir dolutegravir dolutegravir
OR
1raltegravir (Isentress HD) 1200 mg orally, daily. For dosage adjustment in adults with kidney impairment, see raltegravir dosage adjustment. For practice points for initiation of therapy, see Practice points for initial antiretroviral therapy. raltegravir raltegravir raltegravir